Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02950350
Other study ID # Guo Xiaoqing
Secondary ID
Status Not yet recruiting
Phase N/A
First received October 28, 2016
Last updated October 31, 2016
Start date December 2016
Est. completion date December 2023

Study information

Verified date October 2016
Source Shanghai First Maternity and Infant Hospital
Contact Xiaoqing Guo, PHD
Phone 18117203488
Email xiaoqingguo333@163.com
Is FDA regulated No
Health authority China: National Health and Family Planning Commission
Study type Observational

Clinical Trial Summary

Cervical cancer is the most common reproductive malignancy in developing country. Due to local invasion, radical hysterectomy cannot be performed in advanced cervical cancer (FIGO IIB - IVA) , so that radiation combined with chemoradiation (RCTX) is a traditional treatment nowadays. Lack of precise treatment strategies, recurrent ratesand metastasisis high ,and the 5-year survival rate is less than 50%. Therefore, it needs to explore a new strategy for improving the prognosis of advanced cervical cancer.

The prognosis of cervical cancer is closely related to its stages ,while the current FIGO clinical stage is too subjective , for example different gynecologic oncologists may give different diagnosis to the same patient. MRI, CT, PET/CT imaging examinations are commonly used as a referrence for clinical staging, but the sensitivity and specificity are not satisfied. In addition, lymph node metastasis significantly impacts the prognosis of cervical cancer . However, the lymph node invasion is not in current staging criteria.

Precision treatment after surgical staging is recommended by NCCN recently .Surgical staging in patients with advancedcervical cancer is safe and does not delay primary RCTX in few randomized study.Whether overall survival benefit the long-term clinical follow-up surgical staging is unknown.Blocking bilateral uterine artery can effectively reduce the tumor size and increase the operability , which has been conformed in locally advanced cervical cancer. Furthermore, ovarian dysfunction caused by RCTX could be avoided by ovarian transposition via surgical staging .

Based on this, we suggesta new surgical stagingfor patients with advanced cervical cancer , which includinglaparoscopic pelvic and para-aortic lymphadenectomy , uterine blood vessel blocking and ovarian transportation, in order to perform individualized postoperative RCTX, reduce tumor load , preserve ovarian function and improve life quality.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date December 2023
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Pathological diagnosis: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma

- The pathological staging:IIB,IIIA,IIIB,IVA

Exclusion Criteria:

- Underwent surgery or radiation and chemotherapy

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shanghai First Maternity and Infant Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary The recurrence rate 5 years after treatment No
Secondary The transfer rate 5 years after treatment No
Secondary mortality 5 years after treatment No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03477240 - Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients
Withdrawn NCT03146039 - Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB Phase 2
Completed NCT03339765 - Self-Advocacy Serious Game in Advanced Cancer N/A